Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2006

View Archived Issues

Topical phenytoin administration may be useful for nonhealing corneal ulcers

Data on new cancer therapeutics presented at EORTC-NCI-AACR

Emergence of X4 phenotype with maraviroc investigated in HIV patients

Drug-drug interactions, other data on etravirine reported

West Nile virus vaccine candidates show promise

ALK-Abello and Menarini sign Grazax agreement

Hookworm vaccine, treatment evaluated in clinical studies

IRB approval for phase II study of DCVax-Brain in GBM

Elixir raises proceeds to support pipeline development

Norwood Immunology shareholders approve Virosome Biologicals acquisition

Positive data for Multiferon in rabbitpox virus study

Sinclair signs agreement to acquire novel anticaries peptide p1025

Sulforaphane investigated for chemoprevention

Genzyme acquires option for NsGene's neurotrophic factor NsG-33

SB-509 begins phase II study for diabetic neuropathy

Cetrorelix set to begin phase III for BPH

Abuse-resistant PTI-202 safe and well tolerated in phase I study

Genasense studied together with Abraxane and Temodar in advanced melanoma

Atu-027 RNAi more effective in prevention of metastases than gemcitabine

Boehringer Ingelheim ensures access to Viramune in developing countries

M-Vax phase III trial in metastatic melanoma cleared to begin

Interim results suggest antileukemic activity of sapacitabine

Japanese approval sought for nateglinide in combination with insulin sensitizer

Sprycel approved in E.U.

Recent patents divulge novel analgesic agents

Novel agents for treating renal and urological disorders disclosed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...